[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Unaudited Condensed Consolidated Financial Statements](index=3&type=section&id=Item%201.%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The company's Q1 2025 financials show total assets of $489.6 million, a net loss of $10.4 million, and a restatement of the comparative 2024 period [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $88,745 | $114,689 | | Marketable securities | $142,172 | $145,964 | | Accounts receivable | $71,485 | $64,605 | | Total current assets | $350,239 | $351,832 | | Total assets | $489,638 | $491,050 | | **Liabilities & Stockholders' Equity** | | | | Accrued litigation settlement expense | $20,250 | $0 | | Total current liabilities | $85,284 | $89,371 | | Total liabilities | $110,289 | $112,617 | | Total stockholders' equity | $379,349 | $378,433 | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Statement of Operations Summary (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Testing services revenue | $61,921 | $53,837 | | Product revenue | $10,810 | $8,594 | | Patient and digital solutions revenue | $11,954 | $9,618 | | **Total revenue** | **$84,685** | **$72,049** | | Total operating expenses | $98,059 | $94,615 | | Loss from operations | ($13,374) | ($22,566) | | **Net loss** | **($10,353)** | **($19,888)** | | Net loss per share (Basic & Diluted) | ($0.19) | ($0.38) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary (in thousands) | Activity | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($26,584) | ($15,312) | | Net cash provided by investing activities | $1,325 | $27,660 | | Net cash used in financing activities | ($643) | ($1,275) | | **Net (decrease) increase in cash** | **($25,979)** | **$11,099** | | Cash, cash equivalents and restricted cash at end of period | $89,295 | $93,882 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Key notes detail a restatement of Q1 2024 financials, significant revenue from Medicare, a $20.25 million litigation settlement, and a new $50 million stock repurchase program - The company restated its financial statements for the three months ended March 31, 2024, which increased the previously reported net loss from **$16.7 million to $19.9 million** due to corrections in stock-based compensation expense[29](index=29&type=chunk)[31](index=31&type=chunk) - Revenue from Medicare represented approximately **37% of total revenue** for the three months ended March 31, 2025, up from 33% in the same period of 2024[37](index=37&type=chunk) - In the ongoing litigation with Natera, a court overturned a jury verdict against CareDx in February 2025, concluding Natera's patents were invalid, and the previously recognized **$96.3 million liability was derecognized** as of December 31, 2024[67](index=67&type=chunk) - The company reached an agreement-in-principle to settle a Securities Class Action lawsuit for approximately **$20.25 million**, recording a net litigation settlement expense of approximately **$5.4 million** in Q1 2025[77](index=77&type=chunk) - On February 20, 2025, the Board of Directors approved a new Stock Repurchase Program authorizing the purchase of up to **$50 million in common stock** over two years, with no shares repurchased as of March 31, 2025[97](index=97&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Q1 2025 revenue grew 18% year-over-year to $84.7 million, net loss improved to $10.4 million, and the company maintains a strong liquidity position with $230.9 million in cash and marketable securities Q1 2025 Financial Highlights | Metric | Q1 2025 | YoY Change | | :--- | :--- | :--- | | Total Revenue | $84.7 million | +18% | | Testing Services Revenue | $61.9 million | +15% | | Testing Services Volume | ~47,100 | +12% | | GAAP Net Loss | ($10.4 million) | Improved from ($19.9M) | | Cash & Marketable Securities | $230.9 million | N/A | [Results of Operations](index=31&type=section&id=Results%20of%20Operations) - Testing services revenue grew **15% YoY to $61.9 million**, primarily driven by a 12% increase in testing volume across all organs[128](index=128&type=chunk) - Product revenue increased **26% YoY to $10.8 million**, mainly due to higher sales of commercial NGS-based kitted solutions[129](index=129&type=chunk) - Patient and digital solutions revenue rose **24% YoY to $12.0 million**, driven by digital solutions like Ottr software and higher pharmacy sales[130](index=130&type=chunk) - General and administrative expenses decreased by **$7.4 million (24%) YoY**, primarily due to a $6.4 million reduction in stock-based compensation and a $2.0 million decrease in legal expenses[136](index=136&type=chunk) - A litigation settlement expense of **$5.4 million** was recorded in Q1 2025 related to the settlement of the Securities Class Action lawsuit[137](index=137&type=chunk) [Liquidity and Capital Resources](index=32&type=section&id=Liquidity%20and%20Capital%20Resources) - As of March 31, 2025, the company had **$230.9 million in cash, cash equivalents, and marketable securities**, with no outstanding debt[149](index=149&type=chunk) - The company has an accumulated deficit of **$636.6 million** as of March 31, 2025[149](index=149&type=chunk) - Management believes existing cash and expected cash from operations will be sufficient to meet cash requirements for the next 12 months[150](index=150&type=chunk) - A stock repurchase program, renewed in February 2025, allows for the purchase of up to **$50 million in common stock**, with the full amount available as of March 31, 2025[152](index=152&type=chunk)[153](index=153&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=35&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks are interest rate and foreign currency fluctuations, with defined potential impacts on financial statements but no current use of hedging instruments - A hypothetical 100 basis point increase or decrease in interest rates would have an approximate impact of **$0.9 million** on the company's financial statements[160](index=160&type=chunk) - An unfavorable 10% change in foreign currency exchange rates would have negatively impacted product revenue by **$0.4 million** and the balance sheet by **$0.1 million** for the quarter ended March 31, 2025[161](index=161&type=chunk) [Item 4. Controls and Procedures](index=35&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, due to a previously identified material weakness in internal control - Management concluded that as of March 31, 2025, the company's disclosure controls and procedures were **not effective** at a reasonable assurance level[162](index=162&type=chunk) - The ineffectiveness is due to a **material weakness** identified as of December 31, 2024, related to deficiencies in controls for complex and/or non-routine transactions[163](index=163&type=chunk)[164](index=164&type=chunk) - Management is continuing its remediation plan, which includes implementing training, updating accounting policies, and enhancing controls related to stock-based compensation[167](index=167&type=chunk)[169](index=169&type=chunk) [PART II. OTHER INFORMATION](index=37&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) This section references Note 8 for details on legal matters, including litigation with Natera and a securities class action settlement - The company refers to Note 8, "Commitments and Contingencies," for detailed information on its legal proceedings[170](index=170&type=chunk) [Item 1A. Risk Factors](index=37&type=section&id=Item%201A.%20Risk%20Factors) Key risks include a history of net losses, significant reliance on Medicare reimbursement, ongoing litigation, intense competition, and an unremediated material weakness in internal controls - The company has a history of substantial net losses, with an accumulated deficit of **$636.6 million** as of March 31, 2025, and expects to incur net losses for the next several years[172](index=172&type=chunk) - A substantial portion of revenue comes from Medicare, which represented **51% of testing services revenue** for Q1 2025, making financial performance highly sensitive to reimbursement changes[175](index=175&type=chunk) - The company faces significant competition from established diagnostic tests, other molecular diagnostic companies like Natera and Eurofins, and new market entrants[185](index=185&type=chunk)[186](index=186&type=chunk)[187](index=187&type=chunk) - A **material weakness** in internal control over financial reporting, first identified for fiscal year 2022, was not remediated as of December 31, 2024, posing a risk of inaccurate financial reporting[225](index=225&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=46&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company withheld shares to satisfy employee tax obligations and approved a new $50 million stock repurchase program with no shares purchased during the quarter - A total of **137,580 shares** were withheld from employees to cover tax obligations related to vested restricted stock units during the three months ended March 31, 2025[232](index=232&type=chunk) - A new stock repurchase program for up to **$50 million** was approved on February 20, 2025, with no shares repurchased under this program in Q1 2025[233](index=233&type=chunk) [Item 3. Defaults Upon Senior Securities](index=46&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) None [Item 4. Mine Safety Disclosures](index=46&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Not applicable [Item 5. Other Information](index=46&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 trading plans during the quarter - No directors or officers adopted or terminated any Rule 10b5-1 trading plans during the three months ended March 31, 2025[236](index=236&type=chunk) [Item 6. Exhibits](index=47&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including CEO and CFO certifications

[CareDx First Quarter 2025 Results](index=1&type=section&id=CareDx%20First%20Quarter%202025%20Results) [Financial Highlights](index=1&type=section&id=First%20Quarter%20Financial%20Highlights) CareDx reported strong Q1 2025 financial performance with 18% revenue growth to $84.7 million, achieving non-GAAP net income of $5.4 million and adjusted EBITDA of $4.6 million, and maintaining a solid $231 million cash position Q1 2025 Key Financial Metrics | Metric | Q1 2025 | Q1 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | | Total Revenue | $84.7M | $72.0M | +18% | | Testing Services Revenue | $61.9M | $53.8M | +15% | | GAAP Net Loss | ($10.4M) | ($19.9M) | 48% Improvement | | Non-GAAP Net Income/(Loss) | $5.4M | ($1.4M) | Significant Improvement | | Adjusted EBITDA | $4.6M | ($1.9M) | Significant Improvement | | Cash & Marketable Securities | $231M | N/A | N/A | - The company reaffirmed its full-year 2025 guidance for revenue of **$365 million to $375 million** and adjusted EBITDA of **$29 million to $33 million** and maintained its 2027 target of **$500 million** in revenue and **$100 million** in adjusted EBITDA[6](index=6&type=chunk)[10](index=10&type=chunk) [Business Highlights](index=1&type=section&id=First%20Quarter%20Business%20Highlights) CareDx achieved its seventh consecutive quarter of sequential growth in testing services volume, reaching approximately 47,100 tests, while advancing strategic initiatives for AlloSure®, AlloHeme™, and Revenue Cycle Management - Testing services volume grew to approximately **47,100**, marking the seventh consecutive quarter of sequential growth[1](index=1&type=chunk)[6](index=6&type=chunk) - Launched two expanded indications for AlloSure® Testing Services: AlloSure Heart for pediatric patients and AlloSure Kidney for simultaneous pancreas-kidney (SPK) transplant patients[6](index=6&type=chunk) - Advanced the AlloHeme™ pipeline with data presentations at the TANDEM and EBMT conferences[4](index=4&type=chunk)[6](index=6&type=chunk) - Completed the restructuring of the Revenue Cycle Management team to drive Average Selling Price (ASP) growth and launched a strategic initiative to enhance integration with EPIC AURA EMR systems[6](index=6&type=chunk) [Detailed Financial Results](index=1&type=section&id=Q1%202025%20Financial%20Results) Q1 2025 total revenue reached $84.7 million, up 18% YoY, driven by growth across all segments, significantly narrowing GAAP net loss to $10.4 million and achieving non-GAAP net income of $5.4 million Q1 Revenue Breakdown (YoY) | Revenue Segment | Q1 2025 | Q1 2024 | Growth | | :--- | :--- | :--- | :--- | | Testing Services | $61.9M | $53.8M | +15% | | Patient and Digital Solutions | $12.0M | $9.6M | +24% | | Product | $10.8M | $8.6M | +26% | | **Total Revenue** | **$84.7M** | **$72.0M** | **+18%** | - Testing Services revenue for Q1 2025 included a **$1.1 million** write-off for aged receivables, with non-GAAP adjusted testing services revenue at **$63.0 million** excluding this[5](index=5&type=chunk)[7](index=7&type=chunk) Q1 Profitability (YoY) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | GAAP Net Loss | ($10.4M) | ($19.9M) | | GAAP Net Loss per Share | ($0.19) | ($0.38) | | Non-GAAP Net Income/(Loss) | $5.4M | ($1.4M) | | Non-GAAP Diluted Net Income/(Loss) per Share | $0.09 | ($0.03) | | Adjusted EBITDA | $4.6M | ($1.9M) | [Financial Statements](index=4&type=section&id=Financial%20Statements) The financial statements detail an 18% revenue increase and reduced operating loss to $13.4 million, while the balance sheet shows stable total assets at $489.6 million and a strong equity position with no debt [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2025 total revenues were $84.7 million, with operating expenses of $98.1 million, resulting in a $13.4 million loss from operations and a GAAP net loss of $10.4 million, or $0.19 per share Q1 2025 Statement of Operations Highlights (in thousands) | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Total Revenue | $84,685 | $72,049 | | Total Operating Expenses | $98,059 | $94,615 | | Loss from Operations | ($13,374) | ($22,566) | | Net Loss | ($10,353) | ($19,888) | | Net Loss per Share (Basic & Diluted) | ($0.19) | ($0.38) | [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, CareDx held $230.9 million in cash and marketable securities, with total assets of $489.6 million, total liabilities of $110.3 million, and total stockholders' equity of $379.3 million, with no debt Balance Sheet Highlights (in thousands) | Line Item | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $88,745 | $114,689 | | Marketable securities | $142,172 | $145,964 | | Total Assets | $489,638 | $491,050 | | Total Liabilities | $110,289 | $112,617 | | Total Stockholders' Equity | $379,349 | $378,433 | [2025 Guidance](index=2&type=section&id=2025%20Guidance) CareDx reaffirms its full-year 2025 financial guidance, projecting total revenue between $365 million and $375 million and adjusted EBITDA between $29 million and $33 million Full-Year 2025 Guidance | Metric | Guidance Range | | :--- | :--- | | Revenue | $365M - $375M | | Adjusted EBITDA | $29M - $33M | [Non-GAAP Financial Measures & Reconciliations](index=2&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) CareDx uses non-GAAP measures like adjusted EBITDA and non-GAAP net income to clarify core operating performance, reporting Q1 2025 non-GAAP net income of $5.4 million and adjusted EBITDA of $4.6 million - The company uses non-GAAP financial measures to assist investors in assessing operating results by excluding items like stock-based compensation, acquisition-related amortization, and litigation settlement expenses[14](index=14&type=chunk)[15](index=15&type=chunk) Reconciliation of GAAP Net Loss to Non-GAAP Net Income (in thousands) | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **GAAP Net Loss** | **($10,353)** | **($19,888)** | | Stock-based compensation | $8,931 | $16,573 | | Acquisition related-amortization | $1,539 | $1,653 | | Litigation settlement expense | $5,360 | $0 | | Other adjustments | $46 | $214 | | **Non-GAAP Net Income (Loss)** | **$5,424** | **($1,448)** | Reconciliation to Adjusted EBITDA (in thousands) | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **Non-GAAP Net Income (Loss)** | **$5,424** | **($1,448)** | | Interest income | ($2,784) | ($2,885) | | Income tax expense | $157 | $19 | | Depreciation expense | $2,061 | $2,168 | | Other (income) expense, net | ($295) | $290 | | **Adjusted EBITDA** | **$4,563** | **($1,856)** |

Core Viewpoint - A shareholder class action lawsuit has been filed against CareDx, Inc. for allegedly making false and misleading statements regarding its business practices and financial success during the Class Period from April 30, 2020, to November 3, 2022 [1] Group 1: Allegations Against CareDx - CareDx is accused of attributing its financial success to legitimate demand for its testing services, while in reality, it relied on unethical practices, including fraudulent billing to Medicare for unnecessary tests and paying kickbacks to doctors [2] - The company allegedly exploited its RemoTraC home testing program to promote its AlloSure tests, which cost Medicare $2,841 each, to patients who did not require them [2] Group 2: Impact on Stock and Investor Awareness - The lawsuit highlights a series of partial disclosures that revealed the truth about CareDx's operations between October 2021 and November 2022 [3] - On October 28, 2021, CareDx's stock price dropped by $19.34 per share, over 27%, following the announcement of investigations by the DOJ, SEC, and a state regulatory agency related to a False Claims Act investigation [4] - The stock continued to decline, reaching as low as $16.00 per share, as further negative information was disclosed, including executive resignations and a whistleblower complaint [4] Group 3: Legal Proceedings - The investigation aims to determine whether CareDx's board of directors violated securities laws or breached fiduciary duties in connection with the alleged misconduct [5] - Current shareholders who purchased shares before October 28, 2021, are encouraged to seek information about their legal rights and options [6]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ Form 10-K ________________________________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH ...

The Transplant Solutions Company •F E B R U A R Y 2 6 , 2 0 2 5 Click to edit Master text styles Click to edit Master title style Patrick G, Kidney Transplant Recipient Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, i ...

Financial Data and Key Metrics Changes - CareDx reported quarterly revenue of $86.6 million for Q4 2024, representing a 32% year-over-year increase [10] - Full year 2024 revenue reached $334 million, up 19% year-over-year, exceeding the high end of guidance [36] - Adjusted EBITDA for Q4 was $9.8 million, with a full year adjusted EBITDA of $27.8 million, a significant improvement from a loss of $38 million in 2023 [10][42] - The company ended the year with a cash balance of $261 million and no debt, generating $22 million in cash from operations in Q4 [10][44] Business Line Data and Key Metrics Changes - Testing Services revenue for Q4 was $63.8 million, up 37% year-over-year, with approximately 45,500 tests delivered, marking a 14% increase [12][13] - Patient and Digital Solutions revenue was approximately $11.4 million in Q4, representing an 18% year-over-year growth [15] - Lab Products revenue also reached $11.4 million, showing a 23% year-over-year increase, driven by sales of AlloSeq Tx NGS-based HLA typing kits [17] Market Data and Key Metrics Changes - CareDx expanded payer coverage significantly, adding or expanding coverage for 28 million lives for AlloMap Heart and 36 million lives for AlloSure in 2024 [14] - Approximately 5% of CareDx's revenue comes from outside the U.S., with significant potential for growth in the European market [19] Company Strategy and Development Direction - The company aims for long-term profitable growth, targeting $370 million in revenue for 2025 and $500 million by 2027, with a focus on operational excellence and scaling business profitably [10][48] - Key growth drivers include a go-to-market strategy to provide comprehensive solutions to transplant centers, evidence generation to expand payer coverage, and operational excellence to improve efficiency [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant milestones in 2025, particularly with the anticipated implementation of the IOTA program for kidney transplant centers [23][24] - The company is focused on enhancing patient adherence to immunosuppressants through a medication therapy management program launching in 2025 [26] Other Important Information - The company has initiated a share buyback program of up to $50 million over two years, reflecting confidence in its financial position [44] - A significant legal victory reversed a prior $96 million verdict, positively impacting the company's financial statements for 2024 [42] Q&A Session Summary Question: Can you discuss efforts in converting existing accounts with fewer than three solutions to three or more solutions? - Management highlighted the focus on the XynQAPI product for quality reporting and the launch of a medication therapy management program to assist patients with drug interactions, which will drive the use of AlloSure [56] Question: What is the path forward regarding litigation after the reversal of the $96 million verdict? - Management indicated that while an appeal is likely, the reversal allows for strategic capital allocation, including reinvestment in growth opportunities and share buybacks [66] Question: Can you clarify the impact of prior period collections on Q4 revenue and guidance for 2025? - Q4 revenue included approximately $2.2 million from prior period collections, with no contributions from these one-time tests included in the 2025 guidance [72][73] Question: How much of the mid-teens volume growth in 2025 is expected from increased surveillance testing? - Management believes surveillance testing will significantly contribute to mid-teens volume growth, with ongoing discussions to turn on protocols at transplant centers [75] Question: What opportunities exist to improve revenue capture through the billing organization? - The company is focused on enhancing billing processes and systems to improve cash collection, with a new leader in place to drive these initiatives [87][90] Question: Can you remind us of the objectives of the KOAR study? - The KOAR study is a prospective multicenter study evaluating the efficacy of AlloSure Kidney to detect rejection, which is crucial for payer acceptance and product adoption [96]

CareDx (CDNA) Q4 2024 Earnings Call February 27, 2025 08:49 AM ET Company Participants Caroline Corner - Vice President of Finance and Investor RelationsJohn Hanna - President and CEOAbhishek Jain - CFOPrashant Kota - Equity Research AssociateAndrew Cooper - VP - Equity ResearchEduardo Martinez-Montes - Biotechnology Equity Research AssociateThomas DeBourcy - Principal Conference Call Participants None - AnalystMark Massaro - Managing Director - Senior Equity Research AnalystWilliam Bonello - Senior Researc ...

Core Insights - CareDx reported $86.58 million in revenue for Q4 2024, a 32% year-over-year increase, with an EPS of $0.18 compared to -$0.17 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $85.5 million by 1.26%, and the EPS surpassed the consensus estimate of $0.07 by 157.14% [1] Revenue Breakdown - Revenue from Patient and Digital Solutions was $11.39 million, exceeding the average estimate of $10.99 million by analysts, representing an 18.4% year-over-year increase [4] - Revenue from Testing Services reached $63.82 million, compared to the average estimate of $62.20 million, marking a 36.7% year-over-year increase [4] - Revenue from Products was $11.37 million, surpassing the average estimate of $10.83 million, reflecting a 23% year-over-year increase [4] Stock Performance - CareDx shares have returned -8.5% over the past month, while the Zacks S&P 500 composite has changed by -2.3% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Financial Results and Guidance - CareDx, Inc. announced preliminary financial results for Q4 and the year ended December 31, 2024[4]. - The company provided 2025 revenue guidance, details of which are included in the press release[4]. - The financial results and guidance are intended to inform stakeholders and are not deemed "filed" under the Exchange Act[5]. - The company has not disclosed specific financial figures in the provided documents[4]. Corporate Communication - The corporate presentation dated January 13, 2025, is intended to be posted on the company's website[6]. - The press release and corporate presentation are attached as Exhibits 99.1 and 99.2, respectively[9]. - The report was issued on January 13, 2025, indicating the company's commitment to timely communication with investors[12]. Company Information - CareDx, Inc. is registered under the Securities Exchange Act of 1934 and is listed on The Nasdaq Stock Market LLC with the symbol CDNA[2]. - The company is not classified as an emerging growth company under the relevant regulations[3]. - The report was signed by John W. Hanna, President and CEO of CareDx, Inc.[13].

Core Insights - CareDx (CDNA) shares increased by 11.2% to $24.91, following a significant trading volume, contrasting with a 5.2% decline over the past month [1] - The upcoming fourth-quarter 2024 financial results are anticipated to show approximately 30% year-over-year revenue growth, with testing services volume increasing by 14% [2] - The consensus EPS estimate for the quarter is $0.07, reflecting a year-over-year increase of 141.2%, with expected revenues of $85.5 million, up 30.4% from the previous year [3] Earnings and Revenue Expectations - Adjusted EBITDA is projected to be between $25 million and $26 million for the fourth quarter [2] - The consensus EPS estimate has been revised 13.2% higher in the last 30 days, indicating a positive trend that typically leads to price appreciation [4] Industry Context - CareDx is part of the Zacks Medical Services industry, which includes other companies like LifeMD, Inc. (LFMD), that saw a 5.5% increase in its last trading session [4] - LifeMD's EPS estimate remains unchanged at -$0.06, representing a 50% year-over-year change [5]